Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX)
1.6950
+0.0850 (5.28%)
NASDAQ · Last Trade: Nov 6th, 11:10 AM EST
News & Press Releases
What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Callmarketbeat.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes treatment, executives said on the company’s third-quarter earnings call.
The company reported a third
Via MarketBeat · November 6, 2026
Lexicon (LXRX) Q3 2026 Earnings Call Transcriptfool.com
Novo Nordisk milestone payment shapes quarter as HCM readout nears.
Via The Motley Fool · November 5, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q3 2026 Beat Rests on Novo Milestone as SONATA-HCM and ZYNQUISTA Catalysts Loomchartmill.com
Via Chartmill · November 5, 2026
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · November 5, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimateschartmill.com
Via Chartmill · August 6, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rallychartmill.com
Via Chartmill · July 8, 2026
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · October 29, 2026
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice --
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · October 23, 2026
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy --
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · October 21, 2026
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Todayfool.com
An analyst at a prominent research firm initiated coverage of the
Via The Motley Fool · September 28, 2026
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Datamarketbeat.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.
Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv
Via MarketBeat · September 20, 2026
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · September 1, 2026
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · August 31, 2026
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · August 24, 2026
Lexicon (LXRX) Q2 2026 Earnings Call Transcriptfool.com
SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.
Via The Motley Fool · August 13, 2026
Lexicon Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet
Via MarketBeat · August 6, 2026
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · August 6, 2026
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · July 30, 2026
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Study substantially exceeded enrollment target of 500 patients
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · July 27, 2026
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?fool.com
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Via The Motley Fool · June 11, 2026
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · June 3, 2026
Lexicon (LXRX) Q1 2026 Earnings Transcriptfool.com
Lexicon (LXRX) Q1 2026 Earnings Transcript
Via The Motley Fool · June 1, 2026
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · May 28, 2026
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.
By Lexicon Pharmaceuticals, Inc. · Via GlobeNewswire · May 12, 2026
Lexicon Pharmaceuticals Q1 Earnings Call Highlightsmarketbeat.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7.
Chief Executive Officer Mike Exton said the company entered 2026 with o
Via MarketBeat · May 8, 2026